Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry
Open Access
- 1 June 2024
- journal article
- letter
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 17, 551-556
Abstract
The objective of the RAPID registry is to collect information on use of asthma therapy and the long-term effectiveness and safety of dupilumab for asthma.Keywords
This publication has 9 references indexed in Scilit:
- Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryAdvances in Therapy, 2023
- Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension studyThe Lancet Respiratory Medicine, 2022
- Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammationAllergy, 2019
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Commonality of the IL-4/IL-13 pathway in atopic diseasesExpert Review of Clinical Immunology, 2017
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceProceedings of the National Academy of Sciences, 2014
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genesProceedings of the National Academy of Sciences, 2014
- Uncontrolled asthma: A review of the prevalence, disease burden and options for treatmentRespiratory Medicine, 2006